Member Info for potnak

With Tim attending Bio world conference in the first week of June, he must be thinking there is a chance we will get news on the trials before then. As someone stated a couple of weeks back. Why would you attend a conference and book in meetings if all you can say is we're waiting on top line results. IMO, there is a good chance the news is imminent. Possibly as early as tomorrow.

Boysaka - longterm holder here. I will keto buying, whenever funds allow. All the way to a pound and the on to the Peel Hunt note of £1.73. The old saying is "add to a winning position"

Boysaka - longterm holder here. I will keto buying, whenever funds

The data may look good but why isn't pharma knocking on ICR's door. Surely they've seen the data? I honestly think this unnamed company is gathering all the work and data collected so far and putting into a saleable package and I think the original Sierra team are behind it. It might even be a new company set up for this very reason. I'm not being negative but you all have to admit. For such a promising compound, it's weird that it isn't being snapped up and shouted about

Hi HBD. Essentially to use 737 in combo, they will need to treat it as a Phase 1 study. Whether double or triple combo. All compounds might be, individually proven to be safe but when taken together they could cause issues. That will need yo be trialed. Trials cost money and I guess ICR don't want to pay. I'm thinking the unnamed pharma will gather all data, including from the combo candidates, package that up then either raise cash to progress,sell on or maybe do a combo 1a before jumping straight into phase 2. I still have my doubts about 737, if it was really that good why has ICR given to 1 relatively unknown pharma (pronai) and now an unnamed pharma. The terms of the deal mean nothing without knowing how many shares the new company has in issue. If gets P2 combo, its worth 800 million IMO.

I still think that the unnamed pharma has taken on 737 to get it ready for sale. They will put a data package together and tout it around all the major pharma. I also think some of the team behind this are from Sierra 737 team. The 500k shares are a big clue for me. Problem is we don't know how many shares the unlisted has in total. Im sure ICR have some experienced deal makers and hopefully they have just given it away. A small, successful P2a combo trial and 737 will have a 800 million valueation. SAR would potentially get 27% of that. One thing though, in terms of good news, 737 isn't factored into SP, IMO. on the flip side, bad news and the Mm's would slaughter us. 🤷🏻‍♂️

I'd put your sell order in now, if i were you.

Https://www.fiercebiotech.com/biotech/galapagos-acquires-structure-based-drug-discovery-from-sareum

One or maybe 2 are from Belgium. Galapogos are based in Belgium and Sareum had some links with Galapogos in the past. It's a nice theory and think it's as likely as but they already have a TYK2 in GLPG3667, it's in phase 2 for lupus.

Momentum is growing and the exciting thing for me is what will come next. The last RNS indicated "non-dilutive funding" which is probably code for a licence deal but could also mean a JV of some sort. For those here who would like to get news of a TO and think we all would at the right price but the window where a TO could be done is rapidly closing as once a licence deal is done then, we will have our partner who will hopefully push 1801 to market. 1802 will still be on the market and could theoretically be for sale but why would a pharma buy when they could licence? IMO, any pharma looking to make an offer for everything has until a licence deal is inked. Maybe less than 6 weeks? I'm happy with both scenarios but TO rumours may start soon, especially as Tim is BIO 2024 in 3 weeks time, where he is actively trying to book meetings in.

Licence, JV or TO? My gut says licence but if Tim has more than one meeting then we could be in a bidding scenario.

If a wealthy individual missed the party at 10p the putting a 6 figure bet on at 23p this close to newscoukd be seen as almost a dead cert. Without any reported volume it's hard to work out what is going on.

The volume has been really low for the last 2 days so maybe the haven't sold any yet? Unless it is one big transaction? Mm's can hide buys and sells whilst the transaction is still ongoing but I think they have to balance the books within a set amount of time. Basically, I dunno it seems a bit weird. Maybe there is a great demand to forward sell? This is broker to broker type stuff.

Really low volume today. Maybe the Mm's are working one big trade for RF? If they are selling, we should see some chunky trades this afternoon, these will be the buys and then an afterhours corresponding trade for the sell. Bit different to the usual RF MO though. Could be a transfer from RF to an anonymous HNWI? What does level 2 tell us? Anyone?

No reason to exercise the warrants now unless they are selling. They couldve waited until £10 per share and still only paid 10p for them. They will forward sell them this week and maybe into next.

I don't think SAR would be attending if a deal was, already on the table. More likely that disscussions are progressing but data, us still needed so the Board will use the opportunity to talk to a wider audience. I also agree theat the board wouldn't be attending with out some to shout about.

On the warrants and options. It woukd be good to know what the liability is on warrants for RF, HNWI and options for directors etc. If there was to be an RNS, id like to see all liabilities laid out. Get the skeletons out of the cupboard as it were.

Yeah but people are confusing causation and Correlation again. The SP was gradually dropping before the consolidation and kept falling after. The RF fiasco accelerated it further. If PH had managed to get some ii's they would be hero's but with no news due, it was always a big ask.

I don't know what to think about PH. We literally have no evidence that they had anything to do with bringing in RF or the consolidation. PH were engaged to try and get Sareum some institutional investors. To even be eligible for that, you generally need an SP of over a pound. If Sareum wanted investors the consolidation was a cheap way to cheat the system but it didn't play our that way as investors also want a degree of certainty and we were never going to get that until P1a or maybe 2a. As for RF, how do we know it wasn't Hybridan or Strand Hanson the Nomad/financial advisor? I mean, wouldnt our Nominated Financial Advisor advise on finance? If not, the deal would have gone across their desk at the very least. Again, I don't want a witch hunt but all roads lead to the board. End of.

For me, 1801 was, always going to be the loss leader. Even the psoriasis indication is the path of least resistance to market. Almost every milestone that 1801 passes, validates 1802 to the point that a successful 1801 p1a means 1802 can go straight into paitient. The translational studies will incorporate all data learned so far. To the point that 1802 could be licence ready within months.

My questions yesterday re indications that overlap the two TYK2 compounds. I was asking this for a reason. If Company A were thinking of licencing 1801, then surely Company A would be looking at 1802, now patented for some immune indications. However Company B, a cancer-led pharma really wants 1802. This could cause a bidding war where a TO is the most cost-effective way of tying it all up or at the very least drives the value of the compounds higher.